You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir . High-dose combinations of fosamprenavir ( FPV ) and ritonavir ( RTV ) were evaluated in healthy adult subjects in order to select doses for further study in multiple protease inhibitor ( PI ) -experienced patients infected with human immunodeficiency virus type 1 . Two high-dose regimens , FPV 1,400 mg twice a day ( BID ) plus RTV 100 mg BID and FPV 1,400 mg BID plus RTV 200 mg BID , were planned to be compared to the approved regimen , FPV 700 mg BID plus RTV 100 mg BID , in a randomized three-period crossover study . Forty-two healthy adult subjects were enrolled , and 39 subjects completed period 1 . Due to marked hepatic transaminase elevations , predominantly with FPV 1,400 mg BID plus RTV 200 mg BID , the study was terminated prematurely . For FPV 1,400 mg BID plus RTV 100 mg BID , the values for plasma amprenavir ( APV ) area under the concentration-time profile over the dosing interval ( tau ) at steady state [ AUC ( 0-tau ) ] , maximum concentration of drug in plasma ( C ( max ) ) , and plasma concentration at the end of tau at steady state ( C ( tau ) ) were 54 , 81 , and 26 % higher , respectively , and the values for plasma RTV AUC ( 0-tau ) , C ( max ) , and C ( tau ) were 49 % higher , 71 % higher , and 11 % lower , respectively , than those for FPV 700 mg BID plus RTV 100 mg BID . For FPV 1,400 mg BID plus RTV 200 mg BID , the values for plasma APV AUC ( 0-tau ) , C ( max ) , and C ( tau ) were 26 , 48 , and 32 % higher , respectively , and the values for plasma RTV AUC ( 0-tau ) , C ( max ) , and C ( tau ) increased 4.15-fold , 4.17-fold , and 3.99-fold , respectively , compared to those for FPV 700 mg BID plus RTV 100 mg BID . FPV 1,400 mg BID plus RTV 200 mg BID is not recommended due to an increased rate of marked hepatic transaminase elevations and lack of pharmacokinetic advantage . FPV 1,400 mg BID plus RTV 100 mg BID is currently under clinical evaluation in multiple PI-experienced patients .
{"Intervention": ["fosamprenavir ( FPV )", "RTV", "ritonavir ( RTV )", "FPV"], "Outcome": ["values for plasma amprenavir ( APV ) area", "C ( max )", "values for plasma RTV AUC ( 0-tau )", "C ( tau )", "C ( tau", "values for plasma APV AUC ( 0-tau )", "plasma RTV AUC ( 0-tau )", "rate of marked hepatic transaminase elevations", "plasma concentration at the end of tau at steady state", "lack of pharmacokinetic advantage ."], "Participant": ["adult", "Forty-two", "healthy"]}